Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down – Here’s What Happened

Posted by Francis Steltz on Aug 6th, 2026

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $35.74, but opened at $31.68. Collegium Pharmaceutical shares last traded at $31.7870, with a volume of 139,638 shares.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on COLL. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Check Out Our Latest Stock Report on Collegium Pharmaceutical

Collegium Pharmaceutical Price Performance

The stock has a market cap of $1.00 billion, a price-to-earnings ratio of 15.20 and a beta of 0.73. The company has a 50-day moving average of $34.95 and a 200-day moving average of $37.24. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same period in the prior year, the business earned $1.68 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Group One Trading LLC acquired a new position in Collegium Pharmaceutical during the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd increased its holdings in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 318 shares during the period.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.